Comparative Pharmacology
Head-to-head clinical analysis: BENDEKA versus LOMUSTINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENDEKA versus LOMUSTINE.
BENDEKA vs LOMUSTINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bendamustine is a bifunctional mechlorethamine derivative with alkylating and antimetabolite properties. It forms cross-links between DNA strands, leading to DNA synthesis inhibition and apoptosis. The exact mechanism also involves activation of p53-dependent and p53-independent stress pathways, and inhibition of mitotic checkpoints.
Alkylating agent that crosslinks DNA, inhibits DNA synthesis, and produces interstrand crosslinks via chloroethyl carbonium ion formation. Also has carbamoylating activity.
120 mg/m2 intravenously infused over 10 minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles.
130 mg/m² orally as a single dose every 6 weeks; subsequent doses adjusted based on hematologic response.
None Documented
None Documented
Clinical Note
moderateLomustine + Digoxin
"Lomustine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateLomustine + Digitoxin
"Lomustine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateLomustine + Deslanoside
"Lomustine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateLomustine + Acetyldigitoxin
"Lomustine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 40 minutes for bendamustine; active metabolite (gamma-hydroxybendamustine) has half-life of about 3 hours. Clinical context: short half-life allows for rapid clearance, but requires frequent dosing.
Biphasic: initial half-life ~6 hours; terminal half-life ~16-48 hours (mean 24 hours). Metabolites have prolonged half-life up to 72 hours. Clinical context: accumulation with repeated dosing, requiring 6-week intervals.
Primarily renal excretion (approximately 50% as unchanged drug and metabolites); biliary/fecal elimination is minor (<5%).
Renal excretion approximately 50% (as metabolites), biliary/fecal excretion approximately 20%; remainder unaccounted, likely metabolized.
Category C
Category D/X
Alkylating Agent
Alkylating Agent